PMID- 33666353
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20220531
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 8
IP  - 3
DP  - 2021 Jun
TI  - Calculated plasma volume status and outcomes in patients undergoing transcatheter 
      aortic valve replacement.
PG  - 1990-2001
LID - 10.1002/ehf2.13270 [doi]
AB  - AIMS: This study investigated the prognostic value of plasma volume status (PVS) 
      in patients who underwent transcatheter aortic valve replacement (TAVR). METHODS 
      AND RESULTS: Plasma volume status was calculated in 2588 patients who underwent 
      TAVR using data from the Japanese multicentre registry. All-cause mortality and 
      heart failure hospitalization (HFH) within 2 years of TAVR were compared among 
      the PVS quartiles (Q1, PVS < 5.5%; Q2, PVS 5.5-13.5%; Q3, PVS 13.5-21.0%; and Q4, 
      PVS >/= 21.0%). Subgroups were stratified by the PVS cut-off value combined with 
      the New York Heart Association (NYHA) class as follows: low PVS with NYHA I/II 
      (n = 959), low PVS with NYHA III/IV (n = 845), high PVS with NYHA I/II (n = 308), 
      and high PVS with NYHA III/IV (n = 476). The cumulative all-cause mortality and 
      HFH within 2 years of TAVR significantly increased with increasing PVS quartiles 
      [8.5%, 16.8%, 19.2%, and 27.0% (P < 0.001) and 5.8%, 8.7%, 10.3%, and 12.9% 
      (P < 0.001), respectively]. The high-PVS group regardless of the NYHA class had a 
      higher all-cause mortality and HFH [9.6%, 18.2%, 24.5%, and 30.4% (P < 0.001) and 
      6.1%, 10.4%, 14.1%, and 11.3% (P < 0.001)]. In a Cox regression multivariate 
      analysis, the PVS values of Q3 and Q4 had independently increased all-cause 
      mortality [hazard ratio (HR), 1.50 and 1.64 (P = 0.017 and P = 0.008), 
      respectively], and Q4 had independently increased HFH (HR, 1.98, P = 0.005). The 
      low PVS with NYHA III/IV, high PVS with NYHA I/II, and high PVS with NYHA III/IV 
      also had significantly increased all-cause mortality [HR, 1.45, 1.73, and 1.86 
      (P = 0.006, P = 0.002, and P < 0.001), respectively] and HFH [HR, 1.52, 2.21, and 
      1.70 (P = 0.049, P = 0.002, and P = 0.031), respectively]. CONCLUSIONS: Plasma 
      volume status is useful for predicting all-cause mortality and HFH after TAVR.
CI  - (c) 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of European Society of Cardiology.
FAU - Shimura, Tetsuro
AU  - Shimura T
AD  - Department of Cardiology, Toyohashi Heart Center, 21-1 Gobudori, Oyamachyo, 
      Toyohashi, Aichi, 441-8530, Japan.
FAU - Yamamoto, Masanori
AU  - Yamamoto M
AD  - Department of Cardiology, Toyohashi Heart Center, 21-1 Gobudori, Oyamachyo, 
      Toyohashi, Aichi, 441-8530, Japan.
AD  - Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.
FAU - Yamaguchi, Ryo
AU  - Yamaguchi R
AD  - Department of Cardiology, Toyohashi Heart Center, 21-1 Gobudori, Oyamachyo, 
      Toyohashi, Aichi, 441-8530, Japan.
FAU - Adachi, Yuya
AU  - Adachi Y
AD  - Department of Cardiology, Toyohashi Heart Center, 21-1 Gobudori, Oyamachyo, 
      Toyohashi, Aichi, 441-8530, Japan.
FAU - Sago, Mitsuru
AU  - Sago M
AD  - Department of Cardiology, Toyohashi Heart Center, 21-1 Gobudori, Oyamachyo, 
      Toyohashi, Aichi, 441-8530, Japan.
FAU - Tsunaki, Tatsuya
AU  - Tsunaki T
AD  - Department of Cardiology, Toyohashi Heart Center, 21-1 Gobudori, Oyamachyo, 
      Toyohashi, Aichi, 441-8530, Japan.
FAU - Kagase, Ai
AU  - Kagase A
AD  - Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.
FAU - Koyama, Yutaka
AU  - Koyama Y
AD  - Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.
FAU - Otsuka, Toshiaki
AU  - Otsuka T
AD  - Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
AD  - Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan.
FAU - Yashima, Fumiaki
AU  - Yashima F
AD  - Department of Cardiology, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, 
      Japan.
AD  - Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
FAU - Tada, Norio
AU  - Tada N
AD  - Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan.
FAU - Naganuma, Toru
AU  - Naganuma T
AD  - Department of Cardiology, New Tokyo Hospital, Matsudo, Chiba, Japan.
FAU - Yamawaki, Masahiro
AU  - Yamawaki M
AD  - Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Yokohama, 
      Japan.
FAU - Yamanaka, Futoshi
AU  - Yamanaka F
AD  - Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Kanagawa, 
      Japan.
FAU - Shirai, Shinichi
AU  - Shirai S
AD  - Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan.
FAU - Mizutani, Kazuki
AU  - Mizutani K
AD  - Department of Cardiology, Osaka City University Graduate School of Medicine, 
      Osaka, Japan.
FAU - Tabata, Minoru
AU  - Tabata M
AD  - Department of Cardiovascular Surgery, Tokyo Bay Urayasu Ichikawa Medical Center, 
      Urayasu, Chiba, Japan.
FAU - Ueno, Hiroshi
AU  - Ueno H
AD  - Department of Cardiology, Toyama University Hospital, Toyama, Japan.
FAU - Takagi, Kensuke
AU  - Takagi K
AD  - Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Gifu, Japan.
FAU - Watanabe, Yusuke
AU  - Watanabe Y
AD  - Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Hayashida, Kentaro
AU  - Hayashida K
AD  - Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
CN  - OCEAN-TAVI investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20210305
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
SB  - IM
CIN - ESC Heart Fail. 2021 Aug;8(4):3442-3443. PMID: 34121350
MH  - *Aortic Valve Stenosis/diagnosis/surgery
MH  - Humans
MH  - Plasma Volume
MH  - Registries
MH  - *Transcatheter Aortic Valve Replacement
MH  - Treatment Outcome
PMC - PMC8120354
OTO - NOTNLM
OT  - Heart failure
OT  - OCEAN-TAVI
OT  - Plasma volume status
OT  - TAVR
OT  - Transcatheter aortic valve replacement
COIS- M. Yamamoto, N.T., T.N., S.S., K.M., Y.W., H.U., and M.T. are clinical proctors 
      of Edwards Lifesciences and Medtronic. Y.K., K.T., and K.H. are clinical proctors 
      of Edwards Lifesciences. K.H. receives lecture fee from Edwards Lifesciences and 
      Daiichi Sankyo Company. M. Yamamoto receives lecture fee from Edwards 
      Lifesciences, Medtronic, and Daiichi Sankyo Company. S.S. receives lecture fee 
      from Edwards Lifesciences, Medtronic, Abbott Vascular, and Daiichi Sankyo 
      Company. Y.W. receives lecture fee from Edwards Lifesciences and Medtronic. T.N. 
      receives lecture fee from Edwards Lifesciences and Medtronic. K.T. receives 
      lecture fee from Edwards Lifesciences, Abbott, and Daiichi Sankyo Company. N.T. 
      receives lecture fee from Edwards Lifesciences and Medtronic. M.T. receives 
      lecture fee from Edwards Lifesciences, Medtronic, Terumo, Abbott, LivaNova, and 
      Century Medical. K.M. receives lecture fee from Edwards Lifesciences, Abbott, 
      Boston Scientific, Asteras Amgen, and Sanofi. H.U. receives lecture fee from 
      Medtronic. F. Yashima receives lecture fee from Daiichi Sankyo Company. The 
      remaining authors have nothing to disclose.
EDAT- 2021/03/06 06:00
MHDA- 2021/07/03 06:00
PMCR- 2021/03/05
CRDT- 2021/03/05 08:41
PHST- 2020/10/31 00:00 [revised]
PHST- 2020/08/12 00:00 [received]
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/03/06 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
PHST- 2021/03/05 08:41 [entrez]
PHST- 2021/03/05 00:00 [pmc-release]
AID - EHF213270 [pii]
AID - 10.1002/ehf2.13270 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2021 Jun;8(3):1990-2001. doi: 10.1002/ehf2.13270. Epub 2021 Mar 
      5.